Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements Of Cash Flows

v3.19.2
Condensed Consolidated Statements Of Cash Flows - USD ($)
9 Months Ended
Jun. 30, 2019
Jun. 30, 2018
OPERATING ACTIVITIES    
Net loss $ (8,956,909) $ (16,018,878)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 126,084 131,920
Amortization of intangible assets 231,926 206,447
Noncash interest expense 3,627,971 1,730,717
Share-based compensation 1,381,672 1,079,276
Deferred income taxes 20,413 (3,367,000)
Loss on settlement of accounts receivable   3,991,346
Change in fair value of derivative liabilities 246,000 399,000
Other 261,172 (39,155)
Changes in current assets and liabilities:    
(Increase) decrease in accounts receivable (791,272) 2,339,947
(Increase) decrease in inventory (941,188) 114,037
Increase in prepaid expenses and other assets (68,578) (275,586)
(Decrease) increase in accounts payable (46,894) 775,923
Decrease in unearned revenue (187,159) (253,536)
Increase in accrued expenses and other current liabilities 566,557 454,324
Net cash used in operating activities (4,530,205) (8,731,218)
INVESTING ACTIVITIES    
Capital expenditures (74,948) (47,696)
Net cash used in investing activities (74,948) (47,696)
FINANCING ACTIVITIES    
Proceeds from sale of shares in public offering , net of fees and costs 9,131,967  
Installment payments on SWK credit agreement (4,047,207) (642,485)
Proceeds from stock option exercises 200,000 66,000
Net proceeds from sale of shares under common stock purchase agreement 3,600,000 1,922,160
Proceeds from SWK credit agreement   10,000,000
Payment of debt issuance costs   (266,923)
Net cash provided by financing activities 8,884,760 11,078,752
Net increase in cash 4,279,607 2,299,838
CASH AT BEGINNING OF PERIOD 3,759,509 3,277,602
CASH AT END OF PERIOD 8,039,116 5,577,440
Schedule of noncash investing and financing activities:    
Shares issued in connection with common stock purchase agreement   347,081
Amortization of deferred costs related to common stock purchase agreement $ 101,981 $ 56,656